CharlieAJA/iStock via Getty Images
Viatris (NASDAQ:VTRS) shares recorded modest gains in the premarket on Thursday after the Xanax maker announced positive outcomes to several Phase 3 trials alongside better-than-expected financials for Q1 2025.
The Pennsylvania-based drugmaker, which formed in 2020 following the combination of Pfizer (